Industry Segment: Market Brief | Word Count: 225 Words
Attachment: Map

The U.S. government has chosen three vaccine candidates to fund Phase 3 trials under Operation Warp Speed: Moderna's mRNA-1273, the University of Oxford and AstraZeneca's AZD1222, and Pfizer and BioNTech's BNT162. For any of these vaccines to be feasible in "Warp Speed" time, technology transfer (moving the knowledge about and the ability to produce a vaccine from development to manufacturing) has to be carefully and accurately expedited.